HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.

AuthorsS Z Usmani, Q Zhang, K Stratton, P Qu, S Yaccoby, E Hansen, D Steward, S Panozzo, N Petty, A Hoering, S Waheed, F Van Rhee, J Crowley, B Barlogie
JournalLeukemia (Leukemia) Vol. 28 Issue 12 Pg. 2413-5 (Dec 2014) ISSN: 1476-5551 [Electronic] England
PMID25151956 (Publication Type: Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Thalidomide
  • pomalidomide
Topics
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Humans
  • Multiple Myeloma (drug therapy, mortality, pathology)
  • Recurrence
  • Thalidomide (administration & dosage, analogs & derivatives, therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: